Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.

Disclosure: The author does not hold a position in RXRX.

← Back to Free Index

RXRX

Analysis as of: 2026-09-21

Recursion Pharmaceuticals, Inc.

Clinical-stage biotech using its Recursion OS, automated labs, and biopharma partnerships to discover and develop medicines while earning collaboration revenue.

ai automation biotech healthcare software

On Yahoo Finance ...

Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Clinical Proof, Not AI Hype, Drives Upside

The core debate is whether faster discovery turns into real clinical and economic proof before financing pressure dominates. Near-term data and FDA clarity matter more than AI branding because one approval-oriented asset and one more human validation event can reshape the valuation framework.

Analysis

Thesis

Recursion can grow from lumpy collaboration revenue into a multi-asset AI-native biotech if REC-4881 gets a credible approval path, at least one more internal program shows human proof, and the company captures more downstream economics from its data-and-lab engine instead of staying a research-services vendor.

Last Economy Alignment

Cheaper cognition helps because better models can be reused across Recursion’s proprietary data factory, wet labs, and internal assets; the limiter is regulated clinical proof, not software-seat pricing.

Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple

3.8x (from 5 most recent analyses)

Reasoning

The upside is a mix-shift story: less dependence on fee-like collaboration revenue and more value from owned drug economics, milestones, royalties, and a more standardized external workflow offering. If the lead rare-disease asset gets an approval path and a second internal program validates human translation, investors can re-rate the business from speculative AI-biotech tool to multi-asset development engine.

Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary

The main risk is proof conversion, not AI output volume. Recursion must show that its proprietary data, automated labs, and models create approval-oriented assets often enough to justify better partner economics and eventual product revenue. If REC-4881 slips on regulatory design or a second human proof point fails to arrive before financing needs grow, the stock can stay trapped near cash-adjusted option value.

Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Trends

Key Changes

On September 15, 2026, Recursion amended its Tempus agreement: term extended to six years, future annual fees cut to $14m for years 3-5, convenience termination removed, and total data-record access reduced.
On September 15, 2026, Recursion also licensed its oncology RNA foundation model to Tempus for $12m over two years plus linked pathology data access, a small but important direct model-monetization proof point.
No new clinical or FDA-path disclosure arrived in the past week, so the next real repricing gates remain the November 2, 2026 REC-4881 data update and any separate 2H26 FDA feedback.

Thesis update

No material change; the Tempus deal modestly strengthens external monetization, but clinical proof and FDA path clarity still dominate the value case.

Forecast update

A slightly fuller share base and a more measured pace of mix-shift from service revenue to owned economics temper upside despite better recent monetization signals.

Upgrade to Builder to also access: Future Considerations

Last Economy Structure

AI Industrial Score

0.48

They own a big data-and-lab engine that gets smarter as more experiments and partner programs run through it, so cheaper AI helps them more than a normal biotech. But if that engine does not turn into real human results and approved drugs, larger pharma companies can copy parts of the workflow and keep the economics.

Upgrade to Reader to also access: Score Decomposition, Confidence Level

Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility

Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target

$7.22

Upgrade to Reader to also access: Bull Case, Base Case, Bear Case

Next Arc Research